Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13223789 | 0.94 | MAOB (0.49) | MAOBDAOSLC2A1KDM1ATP53 | |
| SCHEMBL24847755 | 0.92 | MAOB (0.50) | MAOBDAOSLC2A1KDM1ATP53 | |
| SCHEMBL13519629 | 0.86 | DAO (0.42) | MAOBDAOSLC2A1KDM1A | |
| SCHEMBL6658550 | 0.86 | MAOB (0.56) | MAOBDAOSLC2A1KDM1ATP53 | |
| SCHEMBL6656793 | 0.86 | MAOB (0.56) | MAOBDAOSLC2A1KDM1AMAOA | |
| SCHEMBL23349399 | 0.86 | MAOB (0.56) | MAOBDAOSLC2A1KDM1ATP53 | |
| SCHEMBL25123284 | 0.84 | GBA1 (0.43) | GBA1TP53SMN1; SMN2 | |
| SCHEMBL6663625 | 0.84 | MAOB (0.57) | MAOBDAOSLC2A1KDM1AMAOA | |
| SCHEMBL22791028 | 0.84 | MAOB (0.42) | MAOBDAOGBA1SLC2A1KDM1A | |
| SCHEMBL25122519 | 0.82 | LMNA (0.39) | MAOBGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4272825-A2 | MTORC MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| WO-2022159688-A9 | DEGRADERS OF GRK2 AND USES THEREOF | SONATA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230159537-A1 | COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | TIANJIN JIKUN MEDICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023278759-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022159688-A1 | DEGRADERS OF GRK2 AND USES THEREOF | CYGNAL THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | UNITY BIOTECHNOLOGY, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-11078199-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-9815834-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815834-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9567334-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567334-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| WO-2016191172-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2016-12-01 | — | — | WO | disclosed |
| US-20160229849-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160200725-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-07-14 | — | — | US | disclosed |
| US-20150306172-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | NOVARTIS AG (CH) | 2015-10-29 | — | — | US | disclosed |
| WO-2015120049-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2015-08-13 | — | — | WO | disclosed |
| US-20100055183-A1 | TRIMEPRAZINE AND ETHOPROPAZINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | MAOB 900/4885DAO 1506/4885GBA1 2796/4885 |
| US-20230159537-A1 | COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | FGFR1, FGFR3, FGFR4 | MAOB 3276/4885DAO 3784/4885GBA1 2856/4885 |
| US-11078199-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | MAOB 1982/4885DAO 3871/4885GBA1 2405/4885 |
| US-20160200725-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | MAOB 1982/4885DAO 3871/4885GBA1 2405/4885 |
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | FGFR1, FGFR3, FGFR2 | MAOB 2210/4885DAO 3784/4885GBA1 2352/4885 |
| US-20100055183-A1 | TRIMEPRAZINE AND ETHOPROPAZINE DERIVATIVES FOR PROMOTING BONE GROWTH | IGFBP5, BMP2, HGF | MAOB 1686/4885DAO 2007/4885GBA1 4259/4885 |
| US-20150306172-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | PPIF, VIP, MAVS | MAOB 2977/4885DAO 4206/4885GBA1 3097/4885 |
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | ACAT1, ARSA, GLA | MAOB 2085/4885DAO 2695/4885GBA1 42/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | MAOB 2438/4885DAO 2086/4885GBA1 2126/4885 |
| US-20160229849-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | MAOB 1982/4885DAO 3871/4885GBA1 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.